Fukushima Medical University – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 39
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: F42AE948FBAEN
Leaflet:

Download PDF Leaflet

Fukushima Medical University – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Fukushima Medical University – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Fukushima Medical University – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Fukushima Medical University human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Fukushima Medical University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Fukushima Medical University’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Fukushima Medical University’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Fukushima Medical University in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Fukushima Medical University’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Fukushima Medical University.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Fukushima Medical University and identify potential opportunities in those areas.
Fukushima Medical University Snapshot
Key Information
Key Facts
Fukushima Medical University – Research and Development Overview
Key Therapeutic Areas
Fukushima Medical University – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Fukushima Medical University – Pipeline Products Glance
Fukushima Medical University Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Fukushima Medical University – Drug Profiles
Dendritic cells + OK-432
  Product Description
  Mechanism of Action
  R&D Progress
Fluorouracil + Epirubicin + Cyclophosphamide + Paclitaxel + Toremifene
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Antiangiogenic Peptide Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
HLA-A*2402 restricted epitope peptide VEGFR1 and VEGFR2 + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
S-1 + Irinotecan
  Product Description
  Mechanism of Action
  R&D Progress
S-1 + irinotecan hydrochloride
  Product Description
  Mechanism of Action
  R&D Progress
VEGFR1 + VEGFR2 + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
VEGFR1-1084 + VEGFR2-169 + gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
VEGFR1-1084 Peptide Vaccine+ VEGFR2-169 Peptide Vaccine+ Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
HLA-A*2402restricted URLC10 + TTK + VEGFR1 + VEGFR2
  Product Description
  Mechanism of Action
  R&D Progress
URLC10 + CDCA1 + VEGFR1 + VEGFR2
  Product Description
  Mechanism of Action
  R&D Progress
Fukushima Medical University – Pipeline Analysis
Fukushima Medical University – Pipeline Products by Therapeutic Class
Fukushima Medical University Pipeline Products By Target
Fukushima Medical University – Pipeline Products by Route of Administration
Fukushima Medical University – Pipeline Products by Molecule Type
Fukushima Medical University - Dormant Projects
Fukushima Medical University – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 39

LIST OF TABLES

Fukushima Medical University – Pipeline by Therapy Area and Indication, 2010
Fukushima Medical University – Pipeline by Stage of Development, 2010
Fukushima Medical University – Monotherapy Products in Pipeline, 2010
Fukushima Medical University – Combination Treatment Modalities in Pipeline, 2010
Fukushima Medical University - Phase II, 2010
Fukushima Medical University - Phase I, 2010
Fukushima Medical University - Pipeline By Therapeutic Class, 2010
Fukushima Medical University - Pipeline By Target, 2010
Fukushima Medical University – Pipeline By Route of Administration, 2010
Fukushima Medical University – Pipeline By Molecule Type, 2010
Fukushima Medical University - Dormant Developmental Projects, 2010 36

LIST OF FIGURES

Fukushima Medical University – Pipeline by Therapy Area and Indication, 2010
Fukushima Medical University – Pipeline by Stage of Development, 2010
Fukushima Medical University – Monotherapy Products in Pipeline, 2010
Fukushima Medical University – Combination Treatment Modalities in Pipeline, 2010
Fukushima Medical University – Pipeline By Therapeutic Class, 2010
Fukushima Medical University - Pipeline By Target, 2010
Fukushima Medical University – Pipeline By Route of Administration, 2010
Fukushima Medical University – Pipeline By Molecule Type, 2010 35

Ask Your Question

Fukushima Medical University – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: